Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALDX Nasdaq 8731 https://www.aldeyra.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aldeyra Therapeutics Inc

Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease - May 24th, 2022 11:00 am
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference - May 23rd, 2022 8:05 pm
Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness - May 18th, 2022 7:26 pm
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness - May 18th, 2022 12:00 pm
Aldeyra Therapeutics (ALDX) Q1 2022 Earnings Call Transcript - May 6th, 2022 12:30 am
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights - May 5th, 2022 11:00 am
Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting - May 4th, 2022 12:30 pm
Aldeyra Therapeutics Announces Chief Financial Officer Transition - Apr 28th, 2022 8:05 pm
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights - Apr 27th, 2022 12:00 pm
Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - Apr 21st, 2022 12:00 pm
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease - Apr 5th, 2022 12:00 pm
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day - Mar 29th, 2022 12:00 pm
Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022 - Mar 22nd, 2022 12:00 pm
Aldeyra Therapeutics (ALDX) Q4 2021 Earnings Call Transcript - Mar 18th, 2022 11:30 am
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights - Mar 17th, 2022 11:00 am
Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference - Mar 14th, 2022 12:00 pm
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights - Mar 10th, 2022 1:00 pm
Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa - Mar 8th, 2022 1:00 pm
Could The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ownership Structure Tell Us Something Useful? - Mar 7th, 2022 4:28 pm
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference - Feb 10th, 2022 1:00 pm